US nod for CSL Behring’s HAE prevention therapy
admin 23rd June 2017 Uncategorised 0US regulators have approved CSL Behring’s Haegarda, the first C1 esterase inhibitor for subcutaneous administration to prevent hereditary angioedema (HAE) attacks in adolescent and adults
More: US nod for CSL Behring’s HAE prevention therapy
Source: News